Endonovo Therapeutics Signs Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical SofPulse

Endonovo Therapeutics (OTCQB: ENDV) a commercial-stage developer of Electroceutical Therapies, today announced a distribution agreement with Plagens Medical Consultants for the distribution of  SofPulse, its non-invasive Electroceutical Therapy for post-operative pain relief and reduction of swelling.

As quoted in the press release:

SofPulse™ is the Company’s FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. SofPulse™ is an easy-to-place, non-invasive device delivering targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery. tMCT is an innovative process using proprietary technology to reduce pain and swelling. The therapy is non-invasive and non-pharmacologic, with no known side effects and no potential for overdose or dependency. SofPulse™ has been used effectively and studied extensively in soft tissue post-operative management. The low levels of microcurrent are completely safe and, in fact, are 1000 times lower than those emitted by a mobile phone.

Click here to read the full press release.